Zentalis Pharmaceuticals, Inc. Common Stock ZNTL
i
Market datapartial · fetched 2026-11-07T07:16:41.253Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-07T00:02:09.594512681Z
FundamentalsAlpha Vantage · unavailable
Zentalis Pharmaceuticals, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 4.28 | 320.6% | 155.6% | |||
| 25Δ | 4.01 | 325.4% | 142.3% | 1.50 | 134.3% | 17.5% |
| 30Δ | 3.74 | 330.3% | 129.1% | 1.56 | 133.9% | 16.0% |
| 35Δ | 3.47 | 335.1% | 115.8% | 1.62 | 133.6% | 14.4% |
| 40Δ | 3.20 | 340.0% | 102.6% | 1.68 | 133.2% | 12.9% |
| 45Δ | 2.92 | 344.8% | 89.3% | 1.74 | 132.8% | 11.4% |
| 50Δ | 2.65 | 349.7% | 76.1% | 1.80 | 132.4% | 9.8% |
| 55Δ | 2.38 | 354.5% | 62.9% | 1.86 | 132.1% | 8.3% |
| 60Δ | 2.11 | 359.3% | 49.6% | 1.92 | 131.7% | 6.8% |
| 65Δ | 1.84 | 364.2% | 36.4% | 1.98 | 131.3% | 5.2% |
| 70Δ | 1.57 | 369.0% | 23.1% | |||
| 75Δ | ||||||
| 80Δ | ||||||
20Δ
- Pseudo strike
- 4.28
- IV
- 320.6%
- B/E move
- 155.6%
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- 4.01
- IV
- 325.4%
- B/E move
- 142.3%
- Pseudo strike
- 1.50
- IV
- 134.3%
- B/E move
- 17.5%
30Δ
- Pseudo strike
- 3.74
- IV
- 330.3%
- B/E move
- 129.1%
- Pseudo strike
- 1.56
- IV
- 133.9%
- B/E move
- 16.0%
35Δ
- Pseudo strike
- 3.47
- IV
- 335.1%
- B/E move
- 115.8%
- Pseudo strike
- 1.62
- IV
- 133.6%
- B/E move
- 14.4%
40Δ
- Pseudo strike
- 3.20
- IV
- 340.0%
- B/E move
- 102.6%
- Pseudo strike
- 1.68
- IV
- 133.2%
- B/E move
- 12.9%
45Δ
- Pseudo strike
- 2.92
- IV
- 344.8%
- B/E move
- 89.3%
- Pseudo strike
- 1.74
- IV
- 132.8%
- B/E move
- 11.4%
50Δ
- Pseudo strike
- 2.65
- IV
- 349.7%
- B/E move
- 76.1%
- Pseudo strike
- 1.80
- IV
- 132.4%
- B/E move
- 9.8%
55Δ
- Pseudo strike
- 2.38
- IV
- 354.5%
- B/E move
- 62.9%
- Pseudo strike
- 1.86
- IV
- 132.1%
- B/E move
- 8.3%
60Δ
- Pseudo strike
- 2.11
- IV
- 359.3%
- B/E move
- 49.6%
- Pseudo strike
- 1.92
- IV
- 131.7%
- B/E move
- 6.8%
65Δ
- Pseudo strike
- 1.84
- IV
- 364.2%
- B/E move
- 36.4%
- Pseudo strike
- 1.98
- IV
- 131.3%
- B/E move
- 5.2%
70Δ
- Pseudo strike
- 1.57
- IV
- 369.0%
- B/E move
- 23.1%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
No recorded observations
Biotechnology
ZURA
Zura Bio Limited (Ticker: ZURA) is a biotechnology firm dedicated to developing breakthrough therapies for autoimmune disorders and rare diseases. The company features a diverse…
More →ZVRA
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The…
More →ZYME
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops and markets biotherapeutic products for the treatment of cancer. The company is headquartered in…
More →AARD
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the…
More →ABCL
AbCellera Biologics Inc. develops an antibody discovery platform. The company is headquartered in Vancouver, Canada.
More →ABEO
Description unavailable
More →